For the Inventor, By the Inventor

Enter inventor name

Palo Alto, CA, United States of America

Naoya Tsurushita

USPTO Granted Patents = 49 (Patent Applications = 9)

CIPO Patents = 13 (Patent Applications = 9)

EPO Patents = 21 (Patent Applications = 27)

Average Co-Inventor Count = 3.5

ph-index = 14

Forward Citations = 955(Granted Patents)

Company Filing History:

Jn Biosciences LLC

Pdl Biopharma, Inc.

The University of Texas System

4. 4 out of 4,447

Eli Lilly and Company

Progenics Pharmaceuticals, Inc.

Facet Biotech Corporation

Gene Techno Science Co., Ltd.

8. 3 out of 1,587

Washington University

Abbott Biotherapeutics Corp.

Abmuno Therapeutics LLC

11. 2 out of 622

National Cheng-Kung University

Chiome Bioscience Inc.

13. 2 out of 136

Kaken Pharmaceutical Company, Ltd.

14. 1 out of 29

Protein Design Labs, Inc.

15. 1 out of 389

Genetics Institute, Inc.

Livtech Inc. — Teikyo University Biotechnology Research Center

Pinteon Therapeutics Inc.

18. 1 out of 17

Cellerant Therapeutics, Inc.

20. 1 out of 51

Abbvie Biotherapeutics Inc.

where one patent can have more than one assignee

Years Active: 2001-2024

Loading Chart...

Loading Chart...

Loading Chart...

Areas of Expertise:

Bifunctional Molecules

Humanized Antibodies

Bispecific Antibodies

Anti-OX40 Antibodies

Antibodies to TIGIT

Hybrid Constant Regions

Anti-CCR5 Antibody

Antibodies Against CTLA4

Nucleic Acid Encoding Antibodies

Immunoglobulin Display Libraries

Fc-Fusion Protein

Tumor Immunotherapy

49 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11993657 - Bifunctional molecules for treatment of immune disorders (2024-05-28),

2. 11723971 - Antibodies to TIGIT (2023-08-15),

3. 11591385 - Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies (2023-02-28),

4. 11332532 - Bispecific antibodies which bind PD-L1 and GITR (2022-05-17),

5. 11072662 - Humanized anti-CLL-1 antibodies (2021-07-27),

6. 10851173 - Anti-OX40 antibodies and methods of using the same (2020-12-01),

7. 10537633 - Antibodies to TIGIT (2020-01-21),

8. 10202461 - Anti-human TROP-2 antibody having an antitumor activity in vivo (2019-02-12),

9. 10196450 - Anti-OX40 antibodies and methods of using the same (2019-02-05),

10. 10053517 - Hybrid constant regions (2018-08-21),

11. 9695246 - Anti-OX40 antibodies and methods of using the same (2017-07-04),

12. 9683036 - Humanized anti-IL-20 antibody and uses thereof (2017-06-20),

13. 9540442 - Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece (2017-01-10),

14. 9527917 - Nucleic acid encoding anti-OX40 antibodies (2016-12-27),

15. 9427464 - Anti-human TROP-2 antibody having an antitumor activity in vivo (2016-08-30),

Title: Naoya Tsurushita: Pioneering Inventor from Palo Alto

Introduction: Naoya Tsurushita is a distinguished inventor based in Palo Alto, California, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Naoya Tsurushita holds several patents in the areas of artificial intelligence, machine learning, and robotics, showcasing his commitment to pushing the boundaries of technological advancement.

Career Highlights: With a career spanning over two decades, Naoya Tsurushita has worked with leading tech companies in Silicon Valley, where he has played a key role in developing cutting-edge technologies that have revolutionized various industries.

Collaborations: Throughout his career, Naoya Tsurushita has collaborated with top researchers, engineers, and scientists, both nationally and internationally, to bring innovative ideas to life and create solutions that have a lasting impact on society.

Conclusion: Naoya Tsurushita's passion for innovation and his relentless pursuit of excellence have solidified his reputation as a visionary inventor, shaping the future of technology and inspiring the next generation of innovators.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…